Nevro Names New Chief Commercial Officer

Nevro Corp, a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Greg Siller has been appointed Senior Vice President and Chief Commercial Officer of Nevro, effective June 19, 2023.  Mr. Siller replaces Niamh Pellegrini, who will be leaving the organization effective June 9.  The company also announced that in conjunction with this appointment, it is updating its revenue guidance for the second quarter of 2023 to a range of $106 to $108 million and plans to update its annual guidance when it reports its second quarter 2023 financial results.

"I am delighted to welcome Greg to the Nevro team," said Kevin Thornal, CEO and President of Nevro. "For the last 17 years, Greg has led the development, implementation and execution of successful commercial strategies and programs for several Stryker businesses, including most recently Stryker's Interventional Spine business.  His proven track record of success and his passion for building high performing commercial organizations will be instrumental as we continue to focus on accelerating revenue growth, developing underpenetrated markets such as painful diabetic neuropathy and non-surgical back pain, and launching new products, including our new HFX iQ system.  I'm confident that Greg's appointment will further bolster our ability to capitalize on the growth opportunities in front of us and accelerate our market performance. I also want to thank Niamh for her contributions over the last four years and wish her success in her future endeavors."

Mr. Siller is an accomplished commercial leader with significant senior management experience, including the last 17 years at Stryker, where he held several positions of increasing responsibility in sales and marketing.  He most recently served as Vice President and General Manager of the Stryker Interventional Spine business since January 2020.  Under Mr. Siller's leadership, this business had strong double-digit sales growth, and he led the strategy to increase R&D investments in the pain and oncology markets to accelerate long-term growth.  Prior to that position, Mr. Siller was Senior Director of Sales at Stryker's Surgical Technologies business from January 2019 to December 2019, where he was responsible for sales that were growing at over twice the market growth rate.  He was also part of the core team that successfully divided the Surgical division into two successful business units. Mr. Siller received a BS in Kinesiology from the University of New Hampshire.       

"I am thrilled to be joining Nevro, and I look forward to furthering its mission of delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment," said Mr. Siller. "Nevro's 10 kHz Therapy provides a unique and highly differentiated technology for patients and physicians in three large, underpenetrated markets.  I look forward to bringing my commercial experience and passion for customers to ensure HFX becomes a standard of care in the treatment of chronic pain."

Source:  Nevro Corp